[1] EI HAJJ N,DITTRICH M,BOCK J,et al.Epigenetic dysregulation in the developing Down syndrome cortex[J].Epigenetics,2016,11(8):563-578.
[2] 袁幼红,苏丽莎,徐燕,等.无创产前基因检测在唐氏综合征筛查中优势分析[J].现代医学,2019,47(9):1139-1142.
[3] TOCH R,SZANTO P,PRODAN Z,et al.Down syndrome and postoperative complications after paediatric cardiac surgery:a propensity-matched analysis[J].Interact Cardiovasc Thorac Surg,2013,17(4):691-697.
[4] CAO J Q,LI C X,WANG R Y,et al.Identification of atherosclerosis-related prioritizing metabolites based on a multi-omics composite network[J].Exp Ther Med,2019,17(5):3391-3398.
[5] RHEE E P,CLISH C B,WENGER J,et al.Metabolomics of chronic kidney disease progression:a case-control analysis in the chronic renal insufficiency cohort study[J].Am J Nephrol,2016,43(5):366-374.
[6] KORSHOLM A S,KJAER T N,ORNSTRUP M J,et al.Comprehensive metabolomic analysis in blood,urine,fat,and muscle in men with metabolic syndrome:a randomized,placebo-controlled clinical trial on the effects of resveratrol after four months' treatment[J].Int J Mol Sci,2017,18(3):554.
[7] YANG W,ZHOU G,ZOU S,et al.Metabonomics of d-glucaro-1,4-lactone in preventing diethylnitrosamine-induced liver cancer in rats[J].Pharm Biol,2018,56(1):643-648.
[8] GRACA G,DUARTE I F,BARROS A S,et al.1H NMR based metabonomics of human amniotic fluid for the metabolic characterization of fetus malformations[J].J Proteome Res,2009,8(8):4144-4150.
[9] JIANG W,QIU Y,NI Y,et al.An automated data analysis pipeline for GC-TOF-MS metabonomics studies[J].J Proteome Res,2010,9(11):5974-5981.
[10] JANSSON J,WILLING B,LUCIO M,et al.Metabolomics reveals metabolic biomarkers of Crohn's disease[J].PLoS One,2009,4(7):e6386.
[11] QIU Y,CAI G,ZHOU B,et al.A distinct metabolic signature of human colorectal cancer with prognostic potential[J].Clin Cancer Res,2014,20(8):2136-2146.
[12] LUO X,YU H,SONG Y,et al.Integration of metabolomic and transcriptomic data reveals metabolic pathway alteration in breast cancer and impact of related signature on survival[J].J Cell Physiol,2019,234(8):13021-13031.
[13] KANEHIAS M,FURUMICHI M,TANABE M,et al.KEGG:new perspectives on genomes,pathways,diseases and drugs[J].Nucleic Acids Res,2017,45(D1):D353-D361.
[14] KACEROVSKY M,VLKOVA B,MUSILOVA I,et al.Amniotic fluid cell-free DNA in preterm prelabor rupture of membranes[J].Prenat Diagn,2018,38(13):1086-1095.
[15] JANG J H,JUNG Y W,SHIM S H,et al.Global gene expression changes of amniotic fluid cell free RNA according to fetal development[J].Eur J Obstet Gynecol Reprod Biol,2017,216:104-110.
[16] BARDANZELLU F,FANOS V.The choice of amniotic fluid in metabolomics for the monitoring of fetus health-update[J].Expert Rev Proteomics,2019,16(6):487-499.
[17] HUANG J,MO J,ZHAO G,et al.Application of the amniotic fluid metabolome to the study of fetal malformations,using Down syndrome as a specific model[J].Mol Med Rep,2017,16(5):7405-7415.
[18] COPPUS A M,FEKKES D,VERHOEVEN W M,et al.Plasma levels of nitric oxide related amino acids in demented subjects with Down syndrome are related to neopterin concentrations[J].Amino Acids,2010,38(3):923-928.
[19] GORSKA-WARSEWICZ H,Laskowski W,Kulykovets O,et al.Food products as sources of protein and amino acids-the case of Poland[J].Nutrients,2018,10(12):1977.
[20] ALI I,WANI W A,HAQUE A,et al.Glutamic acid and its derivatives:candidates for rational design of anticancer drugs[J].Future Med Chem,2013,5(8):961-978.
[21] KAUR G,SHARMA A,XU W,et al.Glutamatergic transmission aberration:a major cause of behavioral deficits in a murine model of Down's syndrome[J].J Neurosci,2014,34(15):5099-5106.
[22] MILAN A M,HUGHES A T,DAVISON A S,et al.The effect of nitisinone on homogentisic acid and tyrosine:a two-year survey of patients attending the National Alkaptonuria Centre,Liverpool[J].Ann Clin Biochem,2017,54(3):323-330.
[23] ALIU E,KANUNGO S,ARNOLD G L.Amino acid disorders[J].Ann Transl Med,2018,6(24):471.
[24] LINERT W,HERLINGER E,JAMESON R F,et al.Dopamine,6-hydroxydopamine,iron,and dioxygen——their mutual interactions and possible implication in the development of Parkinson's disease[J].Biochim Biophys Acta,1996,1316(3):160-168.
[25] KEELE D K,RICHARDS C,BROWN J,et al.Catecholamine metabolism in Down's syndrome[J].Am J Ment Defic,1969,74(1):125-129.
[26] SCHADEWALDT P,BODNER-LEIDECKER A,HAMMEN H W,et al.Significance of L-alloisoleucine in plasma for diagnosis of maple syrup urine disease[J].Clin Chem,1999,45(10):1734-1740.
[27] ROSETY-RODRIGUEZ M,ROSETY I,FORNIELES-GONZALEZ G,et al.A 12-week aerobic training programme reduced plasmatic allantoin in adolescents with Down syndrome[J].Br J Sports Med,2010,44(9):685-687.
[28] CZERSKA M,MIKOLAJEWSKA K,ZIELINSKI M,et al.Today's oxidative stress markers[J].Med Pr,2015,66(3):393-405.
[29] ZITNANOVÁ I,KORYTÁR P,ARUOMA O I,et al.Uric acid and allantoin levels in Down syndrome:antioxidant and oxidative stress mechanisms?[J].Clin Chim Acta,2004,341(1-2):139-146.
[30] TOLUN A A,SCARBROUGH P M,ZHANG H,et al.Systemic oxidative stress,as measured by urinary allantoin and F(2)-isoprostanes,is not increased in Down syndrome[J].Ann Epidemiol,2012,22(12):892-894. |